Prospera^™

For kidney transplant assessment

Covered by Medicare, Prospera is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney.

Through the use of advanced cell-free DNA technology, Prospera increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.

Prospera offers more precise post-transplant rejection assessment

With a 95% negative predictive value, Prospera misses ~3x fewer rejections than serum creatinine.¹ Prospera’s proprietary donor-derived cell-free DNA (dd-cfDNA) technology offers early warning signs of transplant rejection and reduces the likelihood of renal allograft failure with a non-invasive single blood draw.^1,2

Why now?

Organ rejection is a problem

Many kidney transplant failures occur within the first five to ten years^7,8 because organ rejection isn’t caught early enough or treated effectively. As a result, the patient needs a new organ and must start the waitlist process again.

Why Choose Prospera™ for Rejection Assessment?

Built on our deep experience and legacy in cell-free DNA, Prospera™ is:

Access Prospera through our remote service for routine labs

Enroll Now

Find out more about Prospera for Kidney transplant recipients

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor derived cell-free DNA via massively multiplex PCR. J Clin Med. 2018;8(1):pii E19

²Halloran, PF. et al. Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation. Transplantation: June 29, 2022 - doi: 10.1097/TP.0000000000004212

³Bunnapradist, S. Using both fraction and quantity of donor-derived cell-free DNA to detect kidney allograft rejection, J Amer Soc Nephrology 2021, in press

⁴Lum et al. Single center experience comparing two clinically available donor derived cell free DNA tests and review of literature, Transplantation. 2021 doi.org/10.1016/j.tpr.2021.100079

⁵Organ Donation Statistics. U.S. Department of Health and Human Services. U.S. Government Information on Organ Donation and Transplantation. https://www.organdonor.gov/statistics-stories/statistics.html. Published March 31, 2016.

⁶Kidney Disease Statistics for the United States. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Published Dec. 1, 2016.

⁷Stegall et al. Through a Glass Darkly: Seeking Clarity in Preventing Late Kidney Transplant Failure, J Am Soc Nephrol. 2015; 26 (1):20-9

⁸Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal, Am J of Transplantation. 2011; Mar;11(3):450-62.5.

⁹Bunnapradist, S. Using both fraction and quantity of donor-derived cell-free DNA to detect kidney allograft rejection, J Amer Soc Nephrology 2021, in press

Prospera™